| scholarly article | Q13442814 |
| P50 | author | Susan Scanlon | Q57024044 |
| Zhong Yun | Q61163872 | ||
| Alanna R Kaplan | Q61943873 | ||
| Sebastian Oeck | Q85467960 | ||
| Peter M Glazer | Q85479086 | ||
| P2093 | author name string | Yanfeng Liu | |
| Hoon Kim | |||
| P2860 | cites work | Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. | Q50649984 |
| The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials | Q58790609 | ||
| Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial | Q89029416 | ||
| Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer | Q91500865 | ||
| XRCC3 promotes homology-directed repair of DNA damage in mammalian cells | Q24597771 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study | Q27853070 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer | Q28251373 | ||
| Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation | Q28638545 | ||
| (18)F-fluoromisonidazole kinetic modeling for characterization of tumor perfusion and hypoxia in response to antiangiogenic therapy | Q32179417 | ||
| 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. | Q33698756 | ||
| Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. | Q33719652 | ||
| Intermittent hypoxia-induced protein phosphatase 2A activation reduces PC12 cell proliferation and differentiation | Q33759500 | ||
| Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. | Q34300803 | ||
| Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. | Q35049271 | ||
| Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay | Q35940003 | ||
| Autophosphorylation-activated protein kinase phosphorylates and inactivates protein phosphatase 2A | Q36178824 | ||
| Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture. | Q36270034 | ||
| Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma | Q37369575 | ||
| The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1α Levels and Colorectal Cancer Cell Survival under Hypoxia. | Q37654508 | ||
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial | Q38654552 | ||
| Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells | Q39166616 | ||
| Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | Q39348799 | ||
| Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter | Q39525228 | ||
| Combenefit: an interactive platform for the analysis and visualization of drug combinations. | Q39788218 | ||
| Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia | Q40227628 | ||
| Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins. | Q42024219 | ||
| Isolation and initial characterization of the BRCA2 promoter | Q42479799 | ||
| Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. | Q44350742 | ||
| Protein phosphatase 2A associates with Rb2/p130 and mediates retinoic acid-induced growth suppression of ovarian carcinoma cells | Q44547316 | ||
| Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. | Q47673689 | ||
| Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer | Q48110323 | ||
| P433 | issue | 492 | |
| P577 | publication date | 2019-05-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51 | |
| P478 | volume | 11 |
| Q90827979 | Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations |
| Q90324835 | Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance |
| Q92541840 | Harnessing DNA Double-Strand Break Repair for Cancer Treatment |
| Q90671008 | PARP inhibitor combinations in prostate cancer |
| Q95824308 | Preemptive Homology-Directed DNA Repair Fosters Complex Genomic Rearrangements in Hepatocellular Carcinoma |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q89727327 | Therapeutic Application of PARP Inhibitors in Neuro-Oncology |
Search more.